Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

24.16
Delayed Data
As of Jul 21
 -0.16 / -0.66%
Today’s Change
15.15
Today|||52-Week Range
32.54
+44.93%
Year-to-Date

Today’s Trading

Previous close24.32
Today’s open24.49
Day’s range23.83 - 24.61
Volume2,912,758
Average volume (3 months)1,080,336
Market cap$1.6B
Dividend yield--
Data as of 4:00pm ET, 07/21/2017

Growth & Valuation

Earnings growth (last year)+58.33%
Earnings growth (this year)-37.47%
Earnings growth (next 5 years)-25.51%
Revenue growth (last year)+4.25%
P/E ratio53.7
Price/Sales2.98
Price/Book2.23

Competitors

 Today’s
change
Today’s
% change
AAAPAdvanced Accelerator...+0.26+0.63%
QDELQuidel Corp-0.02-0.05%
--Quidel Corp-0.33-1.03%
IMMUImmunomedics Inc+0.04+0.46%
Data as of 4:00pm ET, 07/21/2017

Financials

Next reporting dateAugust 15, 2017
EPS forecast (this quarter)$0.27
Annual revenue (last year)$753.8M
Annual profit (last year)$125.3M
Net profit margin16.62%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts